Skip to main content
Signal8

Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157

$MVMDFPress releaseMay 29, 2026, 8:30 AM ETRead the release

Mountain Valley MD reports advancement of its Quicksome sublingual delivery platform, completing initial formulation work for multiple peptides including BPC-157, GHK-Cu, and retatrutide. The company emphasizes that Quicksome is a delivery technology, not a drug developer, and does not own rights to the underlying peptide molecules. It aims to license the platform to compounding pharmacies to enable needle-free, room-temperature stable administration.

Key figures

Market cagr
8.7%
Glp1 revenue 2024
$46 billion
Cold chain stability temp
40 degrees Celsius
Global peptide market 2025
$141 billion
Global peptide market 2033
$295 billion
Cold chain preservation rate
100%
Cold chain stability duration
5 days
Retatrutide revenue projection 2031
$15 billion to $30 billion

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    MVMDF: Mountain Valley MD Advances Quicksome™ Sublingual Delivery Platform for Compounded Peptide Applications, Reports on Initial Formulation Work Across Multiple Peptides Including BPC-157 — AI Analysis | Signal8